ValnevaVALN
About: Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Employees: 713
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 [Q3] → 12 (+2) [Q4]
0% more ownership
Funds ownership: 0.44% [Q3] → 0.44% (+0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
27% less capital invested
Capital invested by funds: $4.35M [Q3] → $3.16M (-$1.19M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Edward White 21% 1-year accuracy 31 / 149 met price target | 142%upside $17 | Buy Reiterated | 15 Apr 2025 |
Guggenheim Dana Flanders 0% 1-year accuracy 0 / 1 met price target | 113%upside $15 | Buy Maintained | 24 Mar 2025 |
Financial journalist opinion
Based on 36 articles about VALN published over the past 30 days









